Skip to main content
. Author manuscript; available in PMC: 2015 Feb 5.
Published in final edited form as: Leukemia. 2014 Jun 25;29(2):474–482. doi: 10.1038/leu.2014.202

Fig. 1. CSNK1α1 is not involved in bortezomib-triggered cytotoxicity.

Fig. 1

(A), (B) Immunoblotting analysis shows that CSNK1α1 is expressed in MM (MM lines, n=8; MM patient cells, n=5). (C) MM1S cells were treated with bortezomib at the concentrations indicated for 12h (left) or with 20nM bortezomib for time internal, as indicated (right). Whole cells lysates were analyzed with immunoblotting against ubiquitin, CSNK1α1, and GAPDH. GAPDH or Tubulin served as loading controls.